Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...

In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.

US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for ...

This latest FDA decision marks the first approval for SNY's Sarclisa as a first-line treatment for multiple myeloma patients.

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...

Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...